Daniel Carr

List of Publications by Year
in descending order

285 papers	17,653 citations	31976 53 h-index	17105 122 g-index
302 all docs	302 docs citations	302 times ranked	20841 citing authors

#	Article	IF	Citations
1	Drug repurposing: progress, challenges and recommendations. Nature Reviews Drug Discovery, 2019, 18, 41-58.	46.4	2,689
2	Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ: British Medical Journal, 2004, 329, 15-19.	2.3	2,430
3	HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nature Genetics, 2009, 41, 816-819.	21.4	950
4	HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans. New England Journal of Medicine, 2011, 364, 1134-1143.	27.0	815
5	A Randomized Trial of Genotype-Guided Dosing of Warfarin. New England Journal of Medicine, 2013, 369, 2294-2303.	27.0	735
6	Susceptibility to Amoxicillin-Clavulanate-Induced Liver Injury Is Influenced by Multiple HLA Class I and II Alleles. Gastroenterology, 2011, 141, 338-347.	1.3	412
7	Warfarin: almost 60 years old and still causing problems. British Journal of Clinical Pharmacology, 2006, 62, 509-511.	2.4	283
8	Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics and Genomics, 2004, 14, 335-342.	5.7	274
9	Clinical Pharmacogenetics Implementation Consortium Guideline for <i>HLA</i> Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. Clinical Pharmacology and Therapeutics, 2018, 103, 574-581.	4.7	211
10	Association of Liver Injury From Specific Drugs, or Groups ofÂDrugs, With Polymorphisms in HLA and Other Genes in aÂGenome-Wide Association Study. Gastroenterology, 2017, 152, 1078-1089.	1.3	174
11	Phenotype Standardization for Statin-Induced Myotoxicity. Clinical Pharmacology and Therapeutics, 2014, 96, 470-476.	4.7	166
12	Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. Nature Communications, 2014, 5, 4757.	12.8	153
13	Controversies in drug allergy: Testing for delayed reactions. Journal of Allergy and Clinical Immunology, 2019, 143, 66-73.	2.9	144
14	Attitudes and knowledge of hospital pharmacists to adverse drug reaction reporting. British Journal of Clinical Pharmacology, 2001, 51, 81-86.	2.4	134
15	SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 38-69.	3.8	134
16	The danger hypothesisâ€"potential role in idiosyncratic drug reactions. Toxicology, 2002, 181-182, 55-63.	4.2	133
17	Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology, 2003, 192, 23-32.	4.2	132
18	Pharmacogenetics and pharmacogenomics. British Journal of Clinical Pharmacology, 2001, 52, 345-347.	2.4	128

#	Article	IF	Citations
19	Personalized Pharmacogenomics: Predicting Efficacy and Adverse Drug Reactions. Annual Review of Genomics and Human Genetics, 2014, 15, 349-370.	6.2	128
20	Immunological Principles of Adverse Drug Reactions. Drug Safety, 2000, 23, 483-507.	3.2	127
21	Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity. British Journal of Pharmacology, 1999, 126, 1393-1407.	5.4	126
22	SLCO1B1 Genetic Variant Associated With Statin-Induced Myopathy: A Proof-of-Concept Study Using the Clinical Practice Research Datalink. Clinical Pharmacology and Therapeutics, 2013, 94, 695-701.	4.7	124
23	Carbamazepine is not a substrate for P-glycoprotein. British Journal of Clinical Pharmacology, 2001, 51, 345-349.	2.4	123
24	Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components. Journal of Clinical Medicine, 2020, 9, 22.	2.4	122
25	A Review of the Important Role of CYP2D6 in Pharmacogenomics. Genes, 2020, 11, 1295.	2.4	120
26	Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. British Journal of Pharmacology, 2001, 133, 295-305.	5.4	115
27	The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials. Health Technology Assessment, 2014, 18, 1-146.	2.8	114
28	A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions. Pharmacoeconomics, 2016, 34, 771-793.	3.3	111
29	Social media and pharmacovigilance: A review of the opportunities and challenges. British Journal of Clinical Pharmacology, 2015, 80, 910-920.	2.4	103
30	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. Nature Communications, 2021, 12, 2055.	12.8	102
31	Association of Human Leukocyte Antigen Alleles and Nevirapine Hypersensitivity in a Malawian HIV-Infected Population. Clinical Infectious Diseases, 2013, 56, 1330-1339.	5.8	100
32	Risk stratification after paracetamol overdose using mechanistic biomarkers: results from two prospective cohort studies. The Lancet Gastroenterology and Hepatology, 2018, 3, 104-113.	8.1	99
33	Aminoglycoside-induced nephrotoxicity in children. Pediatric Nephrology, 2017, 32, 2015-2025.	1.7	97
34	A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. Gastroenterology, 2019, 156, 1707-1716.e2.	1.3	97
35	Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy. Journal of Clinical Investigation, 2017, 127, 2118-2132.	8.2	90
36	Genetic factors in the predisposition to drug-induced hypersensitivity reactions. AAPS Journal, 2006, 8, E20-E26.	4.4	84

#	Article	IF	Citations
37	Characterization of amoxicillin‐ and clavulanic acid‐specific T cells in patients with amoxicillin‐clavulanate‐induced liver injury. Hepatology, 2015, 62, 887-899.	7.3	83
38	Mechanism of Clozapine-Induced Agranulocytosis. CNS Drugs, 1997, 7, 139-158.	5.9	82
39	Idiosyncratic Drug Reactions. Clinical Pharmacokinetics, 1996, 31, 215-230.	3.5	81
40	Pharmacogenetics: past, present and future. Drug Discovery Today, 2011, 16, 852-861.	6.4	80
41	New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity. Journal of Allergy and Clinical Immunology, 2015, 136, 236-244.	2.9	80
42	Childhood asthma exacerbations and the Arg16 β2-receptor polymorphism: A meta-analysis stratified by treatment. Journal of Allergy and Clinical Immunology, 2016, 138, 107-113.e5.	2.9	80
43	Oral anticoagulation: a critique of recent advances and controversies. Trends in Pharmacological Sciences, 2015, 36, 153-163.	8.7	70
44	The Role of Active Metabolites in Drug Toxicity. Drug Safety, 1994, 11, 114-144.	3.2	69
45	Adverse drug reactions: back to the future. British Journal of Clinical Pharmacology, 2003, 55, 486-492.	2.4	63
46	Plasma Cysteine Deficiency and Decreased Reduction of Nitrososulfamethoxazole with HIV Infection. AIDS Research and Human Retroviruses, 2000, 16, 1929-1938.	1.1	62
47	Direct oral anticoagulants versus warfarin: is new always better than the old?. Open Heart, 2018, 5, e000712.	2.3	61
48	Recommendations for the Use of Social Media in Pharmacovigilance: Lessons from IMI WEB-RADR. Drug Safety, 2019, 42, 1393-1407.	3.2	60
49	Cost‐effectiveness of screening for <i><scp>HLA</scp>‐<scp>A</scp>*31:01</i> prior to initiation of carbamazepine in epilepsy. Epilepsia, 2015, 56, 556-563.	5.1	59
50	Modulation of LAT1 (SLC7A5) transporter activity and stability by membrane cholesterol. Scientific Reports, 2017, 7, 43580.	3.3	59
51	Detection of Drug-Induced Acute Kidney Injury in Humans Using Urinary KIM-1, miR-21, -200c, and -423. Toxicological Sciences, 2016, 152, 205-213.	3.1	58
52	Susceptibility to corticosteroid-induced adrenal suppression: a genome-wide association study. Lancet Respiratory Medicine,the, 2018, 6, 442-450.	10.7	58
53	Drug‐Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. Clinical Pharmacology and Therapeutics, 2019, 106, 245-253.	4.7	58
54	Parsing interindividual drug variability: an emerging role for systems pharmacology. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2015, 7, 221-241.	6.6	57

#	Article	IF	Citations
55	Hepatocellular response to chemical stress in CD-1 mice: Induction of early genes andÎ³-glutamylcysteine synthetase. Hepatology, 2000, 32, 321-333.	7.3	55
56	Quantifying the Metabolic Activation of Nevirapine in Patients by Integrated Applications of NMR and Mass Spectrometries. Drug Metabolism and Disposition, 2010, 38, 122-132.	3.3	55
57	Genomics of Adverse Drug Reactions. Trends in Pharmacological Sciences, 2017, 38, 100-109.	8.7	53
58	The molecular genetics of chemotherapyâ€"induced peripheral neuropathy: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2017, 120, 127-140.	4.4	53
59	Shared Genetic Risk Factors Across Carbamazepineâ€Induced Hypersensitivity Reactions. Clinical Pharmacology and Therapeutics, 2019, 106, 1028-1036.	4.7	52
60	TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity. Pharmacogenetics and Genomics, 2017, 27, 213-222.	1.5	51
61	Pharmacogenomics: Current State-of-the-Art. Genes, 2014, 5, 430-443.	2.4	50
62	Genomeâ€wide association study of inhaled corticosteroid response in admixed children with asthma. Clinical and Experimental Allergy, 2019, 49, 789-798.	2.9	50
63	Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?. British Journal of Cancer, 2020, 123, 207-215.	6.4	50
64	Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout. Rheumatology, 2017, 56, 1729-1739.	1.9	49
65	Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia. Journal of NeuroVirology, 2016, 22, 852-860.	2.1	48
66	Functional validity, role, and implications of heavy alcohol consumption genetic loci. Science Advances, 2020, 6, eaay5034.	10.3	47
67	Identifying the biological pathways underlying human focal epilepsy: from complexity to coherence to centrality. Human Molecular Genetics, 2015, 24, 4306-4316.	2.9	45
68	Genomewide Association Study of Statinâ€Induced Myopathy in Patients Recruited Using the <scp>UK</scp> Clinical Practice Research Datalink. Clinical Pharmacology and Therapeutics, 2019, 106, 1353-1361.	4.7	44
69	Warfarin dosing algorithms: A systematic review. British Journal of Clinical Pharmacology, 2021, 87, 1717-1729.	2.4	43
70	Genetics and the Potential for Predictive Tests in Adverse Drug Reactions. Chemical Immunology and Allergy, 2012, 97, 18-31.	1.7	42
71	Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw545.	3.0	42
72	Global Pharmacogenomics Within Precision Medicine: Challenges and Opportunities. Clinical Pharmacology and Therapeutics, 2020, 107, 57-61.	4.7	42

#	Article	IF	Citations
73	Intracellular Disposition and Metabolic Effects of Zidovudine, Stavudine and Four Protease Inhibitors in Cultured Adipocytes. Antiviral Therapy, 2003, 8, 417-426.	1.0	42
74	Safety assessment of peroxide antimalarials: clinical and chemical perspectives. British Journal of Clinical Pharmacology, 1998, 46, 521-529.	2.4	41
75	Promiscuous T-cell responses to drugs and drug-haptens. Journal of Allergy and Clinical Immunology, 2015, 136, 474-476.e8.	2.9	41
76	A multi-factorial analysis of response to warfarin in a UK prospective cohort. Genome Medicine, 2016, 8, 2.	8.2	41
77	The Effect of Inhibitory Signals on the Priming of Drug Hapten–Specific T Cells That Express Distinct Vβ Receptors. Journal of Immunology, 2017, 199, 1223-1237.	0.8	41
78	A common missense variant of LILRB5 is associated with statin intolerance and myalgia. European Heart Journal, 2017, 38, 3569-3575.	2.2	41
79	SJS/TEN 2019: From science to translation. Journal of Dermatological Science, 2020, 98, 2-12.	1.9	41
80	Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. Journal of Antimicrobial Chemotherapy, 2010, 65, 1889-1893.	3.0	40
81	Detection of Primary T Cell Responses to Drugs and Chemicals in HLA-Typed Volunteers: Implications for the Prediction of Drug Immunogenicity. Toxicological Sciences, 2016, 154, 416-429.	3.1	40
82	Genetic Factors Influencing Warfarin Dose in Black–African Patients: A Systematic Review and Meta–Analysis. Clinical Pharmacology and Therapeutics, 2020, 107, 1420-1433.	4.7	40
83	Altered Adipokine Response in Murine 3T3-F442A Adipocytes Treated with Protease Inhibitors and Nucleoside Reverse Transcriptase Inhibitors. Antiviral Therapy, 2005, 10, 207-213.	1.0	40
84	Pharmacogenetic tests: the need for a level playing field. Nature Reviews Drug Discovery, 2013, 12, 3-4.	46.4	39
85	Calprotectin and Lactoferrin Faecal Levels in Patients with Clostridium difficile Infection (CDI): A Prospective Cohort Study. PLoS ONE, 2014, 9, e106118.	2.5	39
86	Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenetics and Genomics, 2012, 22, 10-19.	1.5	38
87	Tacrine-induced liver damage: an analysis of 19 candidate genes. Pharmacogenetics and Genomics, 2007, 17, 1091-1100.	1.5	37
88	Investigation of inter-individual variability of the one-carbon folate pathway: a bioinformatic and genetic review. Pharmacogenomics Journal, 2009, 9, 291-305.	2.0	37
89	Identifying new antiepileptic drugs through genomics-based drug repurposing. Human Molecular Genetics, 2017, 26, ddw410.	2.9	37
90	CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations. Journal of Antimicrobial Chemotherapy, 2014, 69, 3329-3334.	3.0	36

#	Article	IF	Citations
91	The IL1RN Promoter rs4251961 Correlates with IL-1 Receptor Antagonist Concentrations in Human Infection and Is Differentially Regulated by GATA-1. Journal of Immunology, 2011, 186, 2329-2335.	0.8	35
92	CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia. Blood, 2013, 122, 4253-4258.	1.4	35
93	The effect of fluconazole and ketoconazole on the metabolism of sulphamethoxazole. British Journal of Clinical Pharmacology, 1996, 42, 347-353.	2.4	34
94	Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study. BMC Medicine, 2019, 17, 76.	5.5	34
95	Genetic Association of Co‐Trimoxazole‐Induced Severe Cutaneous Adverse Reactions Is Phenotype‐Specific: HLA Class I Genotypes and Haplotypes. Clinical Pharmacology and Therapeutics, 2020, 108, 1078-1089.	4.7	34
96	Investigation into the multidimensional genetic basis of drug-induced Stevens–Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics, 2007, 8, 1661-1691.	1.3	33
97	A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. Journal of Hepatology, 2022, 76, 275-282.	3.7	33
98	Pharmacogenetics of Adverse Drug Reactions. Advances in Pharmacology, 2018, 83, 155-190.	2.0	32
99	The HLA-A*31:01 allele: influence on carbamazepine treatment. Pharmacogenomics and Personalized Medicine, 2017, Volume10, 29-38.	0.7	31
100	Genetic Risk Factors in Drug‐Induced Liver Injury Due to Isoniazid‐Containing Antituberculosis Drug Regimens. Clinical Pharmacology and Therapeutics, 2021, 109, 1125-1135.	4.7	31
101	Molecular and genetic association of interleukin-6 in tacrine-induced hepatotoxicity. Pharmacogenetics and Genomics, 2007, 17, 961-972.	1.5	30
102	CYP2C19*17 Gain-of-Function Polymorphism Is Associated With Peptic Ulcer Disease. Clinical Pharmacology and Therapeutics, 2013, 93, 195-203.	4.7	30
103	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Standard Reporting and Evaluation Guidelines. JAMA Dermatology, 2017, 153, 587.	4.1	30
104	Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium. Pharmacogenomics, 2017, 18, 931-943.	1.3	30
105	Cellular Uptake of the Atypical Antipsychotic Clozapine Is a Carrier-Mediated Process. Molecular Pharmaceutics, 2018, 15, 3557-3572.	4.6	30
106	A Framework for Multi-Omic Prediction of Treatment Response to Biologic Therapy for Psoriasis. Journal of Investigative Dermatology, 2019, 139, 100-107.	0.7	30
107	Pharmacogenomics for Primary Care: An Overview. Genes, 2020, 11, 1337.	2.4	30
108	Genome-wide association study of warfarin maintenance dose in a Brazilian sample. Pharmacogenomics, 2015, 16, 1253-1263.	1.3	29

#	ARTICLE	IF	CITATIONS
109	Advances in the Pharmacogenomics of Adverse Drug Reactions. Drug Safety, 2016, 39, 15-27.	3.2	29
110	HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients. Frontiers in Immunology, 2021, 12, 661135.	4.8	29
111	Causality Patterns for Detecting Adverse Drug Reactions From Social Media: Text Mining Approach. JMIR Public Health and Surveillance, 2018, 4, e51.	2.6	29
112	Pharmacogenetics of Idiosyncratic Adverse Drug Reactions. Handbook of Experimental Pharmacology, 2010, , 477-491.	1.8	28
113	Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients' and physicians' preferences for testing and service delivery. British Journal of Clinical Pharmacology, 2015, 80, 1149-1159.	2.4	28
114	Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants. Thrombosis Research, 2015, 136, 69-75.	1.7	28
115	A Genome‑wide Association Study of Circulating Levels of Atorvastatin and Its Major Metabolites. Clinical Pharmacology and Therapeutics, 2020, 108, 287-297.	4.7	28
116	Drug therapy for alcohol dependence in primary care in the UK: A Clinical Practice Research Datalink study. PLoS ONE, 2017, 12, e0173272.	2.5	28
117	Folate Augmentation of Treatment â€" Evaluation for Depression (FolATED): randomised trial and economic evaluation. Health Technology Assessment, 2014, 18, 1-160.	2.8	28
118	Predictors and outcomes of increases in creatine phosphokinase concentrations or rhabdomyolysis risk during statin treatment. British Journal of Clinical Pharmacology, 2014, 78, 649-659.	2.4	27
119	HLA-allelotype associations with nevirapine-induced hypersensitivity reactions and hepatotoxicity. Pharmacogenetics and Genomics, 2015, 25, 186-198.	1.5	26
120	Development of the Liverpool Adverse Drug Reaction Avoidability Assessment Tool. PLoS ONE, 2017, 12, e0169393.	2.5	26
121	Warfarin: The End or the End of One Size Fits All Therapy?. Journal of Personalized Medicine, 2018, 8, 22.	2.5	26
122	Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. Pharmacogenetics and Genomics, 2020, 30, 131-144.	1.5	26
123	Beta-lactam-induced immediate hypersensitivity reactions: AÂgenome-wide association study of a deeply phenotyped cohort. Journal of Allergy and Clinical Immunology, 2021, 147, 1830-1837.e15.	2.9	26
124	Identifying cisplatin-induced kidney damage in paediatric oncology patients. Pediatric Nephrology, 2018, 33, 1467-1474.	1.7	25
125	Biomarkers of adverse drug reactions. Experimental Biology and Medicine, 2018, 243, 291-299.	2.4	25
126	Renal function monitoring in heart failure â€" what is the optimal frequency? A narrative review. British Journal of Clinical Pharmacology, 2018, 84, 5-17.	2.4	25

#	Article	IF	Citations
127	Cost‐Effectiveness of Panel Tests for Multiple Pharmacogenes Associated With Adverse Drug Reactions: An Evaluation Framework. Clinical Pharmacology and Therapeutics, 2019, 105, 1429-1438.	4.7	25
128	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. PLoS ONE, 2020, 15, e0227458.	2.5	25
129	Population Pharmacokinetic and Pharmacogenetic Analysis of Nevirapine in Hypersensitive and Tolerant HIV-Infected Patients from Malawi. Antimicrobial Agents and Chemotherapy, 2014, 58, 706-712.	3.2	24
130	Adrenal responses to a low‐dose short synacthen test in children with asthma. Clinical Endocrinology, 2015, 82, 648-656.	2.4	24
131	An assessment of the impact of pharmacogenomics on health disparities: a systematic literature review. Pharmacogenomics, 2017, 18, 1541-1550.	1.3	24
132	Defining drug response for stratified medicine. Drug Discovery Today, 2017, 22, 173-179.	6.4	24
133	Genetic associations with clozapine-induced myocarditis in patients with schizophrenia. Translational Psychiatry, 2020, 10, 37.	4.8	24
134	The International Serious Adverse Events Consortium (iSAEC) phenotype standardization project for drug-induced torsades de pointes. European Heart Journal, 2013, 34, 1958-1963.	2.2	23
135	Effect of *CYP*4F2, *VKORC1*, and *CYP*2C9 in Influencing Coumarin Dose: A Single‐Patient Data Meta‐Analysis in More Than 15,000 Individuals. Clinical Pharmacology and Therapeutics, 2019, 105, 1477-1491.	4.7	23
136	The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 85-99.	3.0	23
137	Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction. Endocrine Connections, 2020, 9, 318-325.	1.9	23
138	CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF. Cytokine, 2016, 83, 139-146.	3.2	22
139	Mass Spectrometric Characterization of Circulating Covalent Protein Adducts Derived from Epoxide Metabolites of Carbamazepine in Patients. Chemical Research in Toxicology, 2017, 30, 1419-1435.	3.3	22
140	Adverse drug reactions and pharmacogenomics: recent advances. Personalized Medicine, 2008, 5, 11-23.	1.5	21
141	The prescribable drugs with efficacy in experimental epilepsies (PDE3) database for drug repurposing research in epilepsy. Epilepsia, 2018, 59, 492-501.	5.1	21
142	Drug-drug interactions and adverse drug reactions: separating the wheat from the chaff. Wiener Klinische Wochenschrift, 2010, 122, 62-64.	1.9	20
143	Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome. Journal of Clinical Lipidology, 2017, 11, 204-214.	1.5	20
144	Genetic regulation of gene expression in the epileptic human hippocampus. Human Molecular Genetics, 2017, 26, 1759-1769.	2.9	20

#	Article	IF	Citations
145	A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVID‐19 (SARS‐COV‐2) treatments. British Journal of Clinical Pharmacology, 2021, 87, 707-711.	2.4	20
146	A population study of clinically actionable genetic variation affecting drug response from the Middle East. Npj Genomic Medicine, 2022, 7, 10.	3.8	20
147	Towards better models and mechanistic biomarkers for drug-induced gastrointestinal injury. , 2017, 172, 181-194.		19
148	A prospective cohort study examining the effectiveness of baclofen in the maintenance of abstinence in alcohol use disorder patients attending a joint liver and alcohol treatment clinic. Alcohol, 2017, 62, 11-15.	1.7	19
149	Roadmap to 2030 for Drug Evaluation in Older Adults. Clinical Pharmacology and Therapeutics, 2022, 112, 210-223.	4.7	19
150	Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with $CYP2B6$ c.516G†'T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis. Antimicrobial Agents and Chemotherapy, 2016, 60, 4511-4518.	3.2	18
151	Precision Dosing in Children. Expert Review of Precision Medicine and Drug Development, 2016, 1, 69-78.	0.7	18
152	New Approaches to Investigate Drug-Induced Hypersensitivity. Chemical Research in Toxicology, 2017, 30, 239-259.	3.3	18
153	Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencing. PLoS ONE, 2019, 14, e0218115.	2.5	18
154	Development of interferon beta-neutralising antibodies in multiple sclerosis—a systematic review and meta-analysis. European Journal of Clinical Pharmacology, 2015, 71, 1287-1298.	1.9	17
155	Safety perspectives on presently considered drugs for the treatment of COVID‐19. British Journal of Pharmacology, 2020, 177, 4353-4374.	5.4	17
156	Has the introduction of direct oral anticoagulants (DOACs) in England increased emergency admissions for bleeding conditions? A longitudinal ecological study. BMJ Open, 2020, 10, e033357.	1.9	17
157	Dimethyl fumarate induced lymphopenia in multiple sclerosis: A review of the literature. , 2021, 219, 107710.		17
158	Genome-wide association study of asthma exacerbations despite inhaled corticosteroid use. European Respiratory Journal, 2021, 57, 2003388.	6.7	17
159	ADRIC: Adverse Drug Reactions In Children — a programme of research using mixed methods. Programme Grants for Applied Research, 2014, 2, 1-184.	1.0	17
160	High‐mobility group box 1 as a predictive biomarker for drug‐resistant epilepsy: A proof‐of‐concept study. Epilepsia, 2022, 63, e1.	5.1	17
161	Ethnic Diversity and Warfarin Pharmacogenomics. Frontiers in Pharmacology, 2022, 13, 866058.	3.5	17
162	Drugs and the retina. Expert Opinion on Drug Safety, 2004, 3, 249-259.	2.4	16

#	Article	IF	Citations
163	*In Vitro* Priming of NaÄ±Ìˆve T-cells with *p*-Phenylenediamine and Bandrowskiâ€™s Base. Chemical Research in Toxicology, 2015, 28, 2069-2077.	3.3	16
164	Development of ELISAs for diagnosis of acute typhoid fever in Nigerian children. PLoS Neglected Tropical Diseases, 2017, 11, e0005679.	3.0	16
165	Application of in Vitro T Cell Assay Using Human Leukocyte Antigen-Typed Healthy Donors for the Assessment of Drug Immunogenicity. Chemical Research in Toxicology, 2018, 31, 165-167.	3.3	16
166	Development, validation and application of a novel HPLC-MS/MS method for the quantification of atorvastatin, bisoprolol and clopidogrel in a large cardiovascular patient cohort. Journal of Pharmaceutical and Biomedical Analysis, 2018, 159, 272-281.	2.8	16
167	Urinary Biomarkers of Aminoglycoside-Induced Nephrotoxicity in Cystic Fibrosis: Kidney Injury Molecule-1 and Neutrophil Gelatinase-Associated Lipocalin. Scientific Reports, 2018, 8, 5094.	3.3	16
168	Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement. European Journal of Clinical Pharmacology, 2019, 75, 1135-1141.	1.9	16
169	Genetic variants associated with T cellâ€“mediated cutaneous adverse drug reactions: A PRISMAâ€compliant systematic reviewâ€”An EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1069-1098.	5.7	16
170	Cardiovascular drugs and COVIDâ€19 clinical outcomes: A living systematic review and metaâ€analysis. British Journal of Clinical Pharmacology, 2021, 87, 4534-4545.	2.4	16
171	Length of Variable Numbers of Tandem Repeats in the Carboxyl Ester Lipase (CEL) Gene May Confer Susceptibility to Alcoholic Liver Cirrhosis but Not Alcoholic Chronic Pancreatitis. PLoS ONE, 2016, 11, e0165567.	2.5	16
172	Validation of a multigenic model to predict seizure control in newly treated epilepsy. Epilepsy Research, 2014, 108, 1797-1805.	1.6	15
173	Serum Mannose-Binding Lectin Concentration, but Not Genotype, Is Associated With Clostridium difficile Infection Recurrence: A Prospective Cohort Study. Clinical Infectious Diseases, 2014, 59, 1429-1436.	5.8	15
174	Systematic review: Baclofen dosing protocols for alcohol use disorders used in observational studies. European Neuropsychopharmacology, 2017, 27, 1077-1089.	0.7	15
175	Research Directions in Genetic Predispositions to Stevensâ€“Johnson Syndrome / Toxic Epidermal Necrolysis. Clinical Pharmacology and Therapeutics, 2018, 103, 390-394.	4.7	15
176	Serum and blisterâ€fluid elevation and decreased epidermal content of highâ€mobility group box 1 protein in drugâ€induced Stevensâ€“Johnson syndrome/toxic epidermal necrolysis. British Journal of Dermatology, 2019, 181, 166-174.	1.5	15
177	Pharmacogenomics in the UK National Health Service: opportunities and challenges. Pharmacogenomics, 2020, 21, 1237-1246.	1.3	15
178	Lack of association between schizophrenia and theCYPZD6 gene polymorphisms. American Journal of Medical Genetics Part A, 1996, 67, 236-237.	2.4	14
179	Monocyte unresponsiveness and impaired IL1Î², TNFÎ± and IL7 production are associated with a poor outcome in Malawian adults with pulmonary tuberculosis. BMC Infectious Diseases, 2015, 15, 513.	2.9	14
180	Misoprostol-induced fever and genetic polymorphisms in drug transporters *SLCO1B1* and *ABCC4* in women of Latin American and European ancestry. Pharmacogenomics, 2015, 16, 919-928.	1.3	14

#	Article	IF	Citations
181	Critical assessment of approaches for molecular docking to elucidate associations of HLA alleles with adverse drug reactions. Molecular Immunology, 2018, 101, 488-499.	2.2	14
182	HLA DRB1*15:01-DQB1*06:02-Restricted Human CD4+ T Cells Are Selectively Activated With Amoxicillin-Peptide Adducts. Toxicological Sciences, 2020, 178, 115-126.	3.1	14
183	Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response. British Journal of Clinical Pharmacology, 2021, 87, 237-255.	2.4	14
184	Characterization of T-Cell Responses to SMX and SMX-NO in Co-Trimoxazole Hypersensitivity Patients Expressing HLA-B*13:01. Frontiers in Immunology, 2021, 12, 658593.	4.8	14
185	Achieving the World Health Organization's vision for clinical pharmacology. British Journal of Clinical Pharmacology, 2016, 81, 223-227.	2.4	13
186	How important is aspirin adherence when evaluating effectiveness of low-dose aspirin?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 219, 1-9.	1.1	13
187	Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis. Alcohol, 2018, 66, 1-7.	1.7	13
188	Improving anticoagulation in sub‑Saharan Africa: What are the challenges and how can we overcome them?. British Journal of Clinical Pharmacology, 2021, 87, 3056-3068.	2.4	13
189	Nilotinib-induced metabolic dysfunction: insights from a translational study using in vitro adipocyte models and patient cohorts. Leukemia, 2019, 33, 1810-1814.	7.2	13
190	Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity. Toxicological Sciences, 2022, 186, 58-69.	3.1	13
191	Investigating the clinical factors and comedications associated with circulating levels of atorvastatin and its major metabolites in secondary prevention. British Journal of Clinical Pharmacology, 2020, 86, 62-74.	2.4	12
192	Anticoagulation in sub‑Saharan Africa: Are direct oral anticoagulants the answer? A review of lessons learnt from warfarin. British Journal of Clinical Pharmacology, 2021, 87, 3699-3705.	2.4	12
193	HLA-DQB1 6672G>C (rs113332494) is associated with clozapine-induced neutropenia and agranulocytosis in individuals of European ancestry. Translational Psychiatry, 2021, 11, 214.	4.8	12
194	HLA Class-II‑Restricted CD8+ T Cells Contribute to the Promiscuous Immune Response in Dapsone-Hypersensitive Patients. Journal of Investigative Dermatology, 2021, 141, 2412-2425.e2.	0.7	12
195	A Review of A Priori Regression Models for Warfarin Maintenance Dose Prediction. PLoS ONE, 2014, 9, e114896.	2.5	12
196	Vitamin D, vitamin D‑binding protein, free vitamin D and COVID-19 mortality in hospitalized patients. American Journal of Clinical Nutrition, 2022, 115, 1367-1377.	4.7	12
197	Pharmacogenomics: Relevance and opportunities for clinical pharmacology. British Journal of Clinical Pharmacology, 2022, 88, 3943-3946.	2.4	12
198	Drug-Specific T Cells in An HIV-Positive Patient with Nevirapine-Induced Hepatitis. Antiviral Therapy, 2006, 11, 393-395.	1.0	12

#	Article	IF	Citations
199	Electronic health records for biological sample collection: feasibility study of statin‐induced myopathy using the <scp>C</scp>linical <scp>P</scp>ractice <scp>R</scp>esearch <scp>D</scp>atalink. British Journal of Clinical Pharmacology, 2014, 77, 831-838.	2.4	11
200	HLA-A 31:01 is not associated with the development of methotrexate pneumonitis in the UK population: results from a genome-wide association study. Annals of the Rheumatic Diseases, 2017, 76, e51-e51.	0.9	11
201	Open letter on access to the BIA 10-2474 clinical trial data. Lancet, The, 2017, 389, 156.	13.7	11
202	Genetic and nongenetic factors that may predispose individuals to allergic drug reactions. Current Opinion in Allergy and Clinical Immunology, 2018, 18, 325-332.	2.3	11
203	Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepine. British Journal of Clinical Pharmacology, 2021, 87, 2572-2588.	2.4	11
204	Combined analysis of transcriptomic and genetic data for the identification of loci involved in glucocorticosteroid response in asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1238-1243.	5.7	11
205	Probenecid Increases the Concentration of 7-Chlorokynurenic Acid Derived from the Prodrug 4-Chlorokynurenine within the Prefrontal Cortex. Molecular Pharmaceutics, 2021, 18, 113-123.	4.6	11
206	The adverse effects of drugs. British Journal of Hospital Medicine, 1999, 60, 348-352.	0.2	10
207	An Investigation of Disagreement in Causality Assessment of Adverse Drug Reactions. Pharmaceutical Medicine, 2011, 25, 17-24.	1.9	10
208	Treatment of paracetamol overdose: room for improvement?. Lancet, The, 2014, 383, 672-674.	13.7	10
209	A pilot randomised controlled trial to assess the utility of an e-learning package that trains users in adverse drug reaction causality. International Journal of Pharmacy Practice, 2015, 23, 447-455.	0.6	10
210	Hemolytic anemia in two patients with glioblastoma multiforme: A possible interaction between vorinostat and dapsone. Journal of Oncology Pharmacy Practice, 2015, 21, 220-223.	0.9	10
211	Epidemiology of alcohol dependence in UK primary care: Results from a large observational study using the Clinical Practice Research Datalink. PLoS ONE, 2017, 12, e0174818.	2.5	10
212	TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy. Clinical Infectious Diseases, 2020, 70, 2062-2072.	5.8	10
213	Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritisation. Pharmacogenomics Journal, 2020, 20, 621-628.	2.0	10
214	Associations between occupation and heavy alcohol consumption in UK adults aged 40–69 years: a cross-sectional study using the UK Biobank. BMC Public Health, 2021, 21, 190.	2.9	10
215	T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab. , 2021, 9, e002521.		10
216	Factors Affecting Patient and Physician Engagement in Remote Health Care for Heart Failure: Systematic Review. JMIR Cardio, 2022, 6, e33366.	1.7	10

#	Article	IF	Citations
217	A reference set of clinically relevant adverse drug-drug interactions. Scientific Data, 2022, 9, 72.	5.3	10
218	Stable warfarin dose prediction in sub‐Saharan African patients: A machine‐learning approach and external validation of a clinical dose–initiation algorithm. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 20-29.	2.5	10
219	Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy. BMJ Open, 2015, 5, e009566.	1.9	9
220	Repurposing Statins for Renal Protection: Is It a Class Effect?. Clinical and Translational Science, 2018, 11, 100-102.	3.1	9
221	Characterization of Clozapine-Responsive Human T Cells. Journal of Immunology, 2020, 205, 2375-2390.	0.8	9
222	Deciphering Adverse Drug Reactions:<i>In Vitro</i>Priming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01. Toxicological Sciences, 2021, 183, 139-153.	3.1	9
223	Anticipating, investigating and managing the adverse effects of drugs. Clinical Medicine, 2005, 5, 23-26.	1.9	8
224	Clinical management of HIV-associated lipodystrophy. Current Opinion in Lipidology, 2009, 20, 309-314.	2.7	8
225	Development of predictive genetic tests for improving the safety of new medicines: the utilization of routinely collected electronic health records. Drug Discovery Today, 2014, 19, 361-366.	6.4	8
226	Telmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistance<i>in vitro</i>. Diabetes and Vascular Disease Research, 2018, 15, 233-242.	2.0	8
227	Developing and Validating a Clinical Warfarin Dose‐Initiation Model for Black‐African Patients in South Africa and Uganda. Clinical Pharmacology and Therapeutics, 2021, 109, 1564-1574.	4.7	8
228	HLA Allele‐Restricted Immune-Mediated Adverse Drug Reactions: Framework for Genetic Prediction. Annual Review of Pharmacology and Toxicology, 2022, 62, .	9.4	8
229	The applications of pharmacogenetics to prescribing: what is currently practicable?. Clinical Medicine, 2009, 9, 493-495.	1.9	7
230	Genetic testing for prevention of severe drug-induced skin rash. The Cochrane Library, 2019, 7, CD010891.	2.8	7
231	Cardiovascular drugs and COVID‐19 clinical outcomes: a systematic review and meta‐analysis of randomized controlled trials. British Journal of Clinical Pharmacology, 2022, 88, 3577-3599.	2.4	7
232	Similarity and consistency assessment of three major online drug‐drug interaction resources. British Journal of Clinical Pharmacology, 2022, 88, 4067-4079.	2.4	7
233	Genetic testing for prevention of severe drug-induced skin rash. The Cochrane Library, 2013, , .	2.8	6
234	Is the Interleukin 8 Promoter Polymorphism rs4073/-251T >A Associated With Clostridium difficile Infection?. Clinical Infectious Diseases, 2014, 58, e148-e151.	5.8	6

#	Article	IF	Citations
235	Copy number variation in exportin-4 (XPO4) gene and its association with histological severity of non-alcoholic fatty liver disease. Scientific Reports, 2015, 5, 13306.	3.3	6
236	Trastuzumab uptake in HER2-positive breast cancer patients: a systematic review and meta-analysis of observational studies. Critical Reviews in Oncology/Hematology, 2018, 130, 92-107.	4.4	6
237	Nonmedical prescriber experiences of training and competence to report adverse drug reactions in the UK. Journal of Clinical Pharmacy and Therapeutics, 2019, 44, 78-83.	1.5	6
238	Identification of ROBO2 as a Potential Locus Associated with Inhaled Corticosteroid Response in Childhood Asthma. Journal of Personalized Medicine, 2021, 11, 733.	2.5	6
239	Pharmacogenomics of Drug Hypersensitivity. Immunology and Allergy Clinics of North America, 2022, 42, 335-355.	1.9	6
240	Lipodystrophy in Patients with HIV-1 Infection: Effect of Stopping Protease Inhibitors on Tnf-α and Tnf-Receptor Levels, and on Metabolic Parameters. Antiviral Therapy, 2004, 9, 879-887.	1.0	6
241	Drug hypersensitivity reactions in patients with HIV disease. Expert Review of Clinical Immunology, 2007, 3, 395-410.	3.0	5
242	CKMGlu83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	5
243	HLA- and immune-mediated adverse drug reactions: Another hit with vancomycin. Journal of Allergy and Clinical Immunology, 2019, 144, 44-45.	2.9	5
244	Alcohol-related brain injury: An unrecognized problem in acute medicine. Alcohol, 2020, 88, 49-53.	1.7	5
245	Serotonin re-uptake transporter gene polymorphisms are associated with imatinib-induced diarrhoea in chronic myeloid leukaemia patients. Scientific Reports, 2020, 10, 8394.	3.3	5
246	Genome-Wide association between EYA1 and Aspirin-induced peptic ulceration. EBioMedicine, 2021, 74, 103728.	6.1	5
247	UK veterinary professionals' perceptions and experiences of adverse drug reaction reporting. Veterinary Record, 2022, 191, .	0.3	5
248	An integrative *in silico* system for predicting dysregulated genes in the human epileptic focus: Application to SLC transporters. Epilepsia, 2016, 57, 1467-1474.	5.1	4
249	TEMPORARY REMOVAL: Reference intervals for putative biomarkers of drug-induced liver injury and liver regeneration in healthy human volunteers. Journal of Hepatology, 2018, , .	3.7	4
250	Processes and barriers to implementation of point-of-care genotype-guided dosing of warfarin into UK outpatient anticoagulation clinics. Pharmacogenomics, 2019, 20, 599-608.	1.3	4
251	A randomised controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis. Scientific Reports, 2020, 10, 1796.	3.3	4
252	Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 100-103.	3.0	4

#	Article	IF	Citations
253	Drug metabolism and drug toxicity. Inflammopharmacology, 2001, 9, 183-199.	3.9	3
254	Editorial Commentary: Statins, Immunomodulation, and Infections: A Complex and Unresolved Relationship. Clinical Infectious Diseases, 2014, 58, 357-358.	5.8	3
255	A Randomized Controlled Trial of Extended Brief Intervention for Alcohol-Dependent Patients in an Acute Hospital Setting. Alcohol and Alcoholism, 2016, 51, 584-592.	1.6	3
256	Informatics investigations into anti-thyroid drug induced agranulocytosis associated with multiple HLA-B alleles. PLoS ONE, 2020, 15, e0220754.	2.5	3
257	Drug-specific T cells in an HIV-positive patient with nevirapine-induced hepatitis. Antiviral Therapy, 2006, 11, 393-5.	1.0	3
258	Mechanisms of Adverse Drug Reactions. , 0, , 85-103.		3
259	Identification of susceptible HLA class II coâ€amoxiclav genotypes based on the analysis of drugâ€specific Tâ€cells from patients with liver injury. Clinical and Translational Allergy, 2014, 4, O3.	3.2	2
260	Genetic Predisposition to Anticonvulsant Hypersensitivity. Clinical Pharmacology and Therapeutics, 2019, 106, 919-922.	4.7	2
261	Precision medicine in drug safety. Current Opinion in Toxicology, 2020, 23-24, 87-97.	5.0	2
262	Assessing the impact of alcohol consumption on the genetic contribution to mean corpuscular volume. Human Molecular Genetics, 2021, 30, 2040-2051.	2.9	2
263	An association study of common SNPs in SREBPâ€2 and SCAP genes with simvastatin response in Saudi patients. FASEB Journal, 2007, 21, A182.	0.5	2
264	Characterisation of Nilotinib Transport in Chronic Myeloid Leukaemia Cells.. Blood, 2007, 110, 2364-2364.	1.4	2
265	Understanding drug interactions. Nursing and Residential Care, 2002, 4, 312-317.	0.1	1
266	Pharmacogenetics in the treatment of chronic lymphocytic leukemia: what does the future hold?. Pharmacogenomics, 2014, 15, 897-900.	1.3	1
267	Adrenal suppression with inhaled corticosteroids: the seed and the soil â€" Authors' reply. Lancet Respiratory Medicine,the, 2018, 6, e20.	10.7	1
268	Characterization of Teicoplanin-Specific T-Cells from Drug NaÃ¯ve Donors Expressing HLA-A*32:01. Chemical Research in Toxicology, 2022, 35, 199-202.	3.3	1
269	Chromosomal Region 11p14.1 is Associated with Pharmacokinetics and Pharmacodynamics of Bisoprolol. Pharmacogenomics and Personalized Medicine, 2022, Volume 15, 249-260.	0.7	1
270	Institutional Profile: The Wolfson Centre for Personalised Medicine, University of Liverpool, Liverpool, UK. Pharmacogenomics, 2013, 14, 861-867.	1.3	0

#	Article	IF	Citations
271	Characterization of amoxicillin and clavulanicâ€acidâ€responsive CD4+ And CD8+ Tâ€cells in patients with coâ€amoxiclavâ€induced liver injury. Clinical and Translational Allergy, 2014, 4, P42.	3.2	0
272	Genomeâ€wide association study of nevirapine hypersensitivity in a malawian HIVâ€infected population. Clinical and Translational Allergy, 2014, 4, P125.	3.2	0
273	Letter to the Editor: Response to Costa et al.. European Neuropsychopharmacology, 2018, 28, 658.	0.7	0
274	Nucleic acid based therapies: developing frontier for precision medicine. BMJ: British Medical Journal, 2018, 360, k223.	2.3	0
275	Inflammatory Bowel Disease: A Personalized Approach. Frontiers in Pediatrics, 2020, 8, 620545.	1.9	0
276	Pharmacogenetics of Adverse Drug Reactions. Advances in Predictive, Preventive and Personalised Medicine, 2015, , 109-156.	0.6	0
277	Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT. Efficacy and Mechanism Evaluation, 2019, 6, 1-168.	0.7	0
278	Metabolic Mechanisms. , 0, , 57-75.		0
279	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
280	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
281	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
282	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
283	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
284	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
285	Platelet-derived growth factor D expression in adrenal cells is modulated by corticosteroids: putative role in adrenal suppression. Pediatric Research, 2023, 93, 97-101.	2.3	0